In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
|Articles|September 23, 2022
AJMC® in the Press, September 23, 2022
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
An article by
Advertisement
Related to this article
GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non–drug care up front.
This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.
Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
3
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
4
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
5